BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by ‍Andreessen Horowitz, 8VC, AME Cloud Ventures, and Innovation Endeavors. BigHat operates out of San Carlos, CA, in the San Francisco Bay Area. We pride ourselves on our team-oriented, inclusive, remote-friendly, and family-centric culture. BigHat Biosciences is designing safer, more effective antibody therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies. We are applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat operates out of San Mateo, CA, in the San Francisco Bay Area. We pride ourselves on our team-oriented, inclusive, remote-friendly, and family-centric culture. We are a novel protein therapeutics company and developer of an AI-guided antibody design platform.